AQR Capital Management LLC increased its position in shares of Mylan NV (NASDAQ:MYL) by 11.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,247,227 shares of the company’s stock after buying an additional 1,111,009 shares during the quarter. AQR Capital Management LLC owned about 2.18% of Mylan worth $213,473,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Advisory Services Network LLC grew its stake in shares of Mylan by 170.0% during the second quarter. Advisory Services Network LLC now owns 1,520 shares of the company’s stock worth $29,000 after purchasing an additional 957 shares in the last quarter. NuWave Investment Management LLC grew its stake in shares of Mylan by 1,111.0% during the second quarter. NuWave Investment Management LLC now owns 2,192 shares of the company’s stock worth $42,000 after purchasing an additional 2,011 shares in the last quarter. Rational Advisors LLC boosted its stake in Mylan by 1,111.0% in the second quarter. Rational Advisors LLC now owns 2,192 shares of the company’s stock valued at $42,000 after acquiring an additional 2,011 shares in the last quarter. Signaturefd LLC boosted its stake in Mylan by 271.8% in the second quarter. Signaturefd LLC now owns 3,376 shares of the company’s stock valued at $64,000 after acquiring an additional 2,468 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its stake in Mylan by 22.5% in the second quarter. Rockefeller Capital Management L.P. now owns 3,755 shares of the company’s stock valued at $71,000 after acquiring an additional 689 shares in the last quarter. 84.75% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have issued reports on the stock. Credit Suisse Group restated a “buy” rating and issued a $34.50 price objective on shares of Mylan in a research note on Wednesday, July 31st. Citigroup set a $26.00 price objective on shares of Mylan and gave the company a “buy” rating in a research note on Wednesday, July 31st. BidaskClub downgraded shares of Mylan from a “hold” rating to a “sell” rating in a research note on Tuesday, October 1st. TheStreet cut shares of Mylan from a “c-” rating to a “d+” rating in a report on Friday, August 2nd. Finally, ValuEngine raised shares of Mylan from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. Mylan currently has a consensus rating of “Buy” and a consensus target price of $30.03.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, July 29th. The company reported $1.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.08. Mylan had a net margin of 0.30% and a return on equity of 18.93%. The company had revenue of $2.85 billion for the quarter, compared to the consensus estimate of $2.82 billion. During the same quarter last year, the firm posted $1.07 earnings per share. Mylan’s revenue was up 1.5% on a year-over-year basis. On average, equities analysts expect that Mylan NV will post 4.27 EPS for the current fiscal year.
In related news, Director Richard A. Mark purchased 4,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were bought at an average cost of $20.97 per share, for a total transaction of $83,880.00. Following the transaction, the director now owns 4,000 shares of the company’s stock, valued at $83,880. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sjoerd S. Vollebregt bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was acquired at an average price of $19.11 per share, for a total transaction of $191,100.00. Following the completion of the acquisition, the director now directly owns 18,258 shares in the company, valued at $348,910.38. The disclosure for this purchase can be found here. Insiders have purchased a total of 83,859 shares of company stock worth $1,628,752 in the last ninety days. 0.81% of the stock is currently owned by insiders.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.